WO2003055979A3 - ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS - Google Patents
ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLySInfo
- Publication number
- WO2003055979A3 WO2003055979A3 PCT/US2002/036496 US0236496W WO03055979A3 WO 2003055979 A3 WO2003055979 A3 WO 2003055979A3 US 0236496 W US0236496 W US 0236496W WO 03055979 A3 WO03055979 A3 WO 03055979A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blys
- antibodies
- immunospecifically bind
- present
- related molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02802570A EP1456347A4 (en) | 2001-11-16 | 2002-11-14 | Antibodies that immunospecifically bind to blys |
CA002467521A CA2467521A1 (en) | 2001-11-16 | 2002-11-14 | Antibodies that immunospecifically bind to blys |
AU2002364954A AU2002364954A1 (en) | 2001-11-16 | 2002-11-14 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33146901P | 2001-11-16 | 2001-11-16 | |
US60/331,469 | 2001-11-16 | ||
US34081701P | 2001-12-19 | 2001-12-19 | |
US60/340,817 | 2001-12-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003055979A2 WO2003055979A2 (en) | 2003-07-10 |
WO2003055979A3 true WO2003055979A3 (en) | 2003-12-18 |
Family
ID=26987779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036496 WO2003055979A2 (en) | 2001-11-16 | 2002-11-14 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1456347A4 (en) |
AU (1) | AU2002364954A1 (en) |
CA (1) | CA2467521A1 (en) |
WO (1) | WO2003055979A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
EP2319527A3 (en) | 1999-01-25 | 2011-10-12 | Biogen Idec MA Inc. | BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
GEP20053685B (en) | 1999-08-17 | 2005-12-12 | Biogen Inc | BAFF Receptor (BCMA), an Immunoregulatory Agent |
UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
PT2281843T (en) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
AU2004233164B2 (en) | 2003-03-28 | 2009-10-08 | Biogen Ma Inc. | Truncated BAFF receptors |
KR20060027801A (en) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
WO2005012531A2 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
KR100923828B1 (en) * | 2004-03-31 | 2009-10-27 | 캐논 가부시끼가이샤 | Gold-binding protein |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
JP5570681B2 (en) * | 2004-08-31 | 2014-08-13 | 興和株式会社 | Anti-human BAFF antibody |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
AU2006344395B2 (en) | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
EP2139517B1 (en) | 2007-03-27 | 2013-05-29 | Zymogenetics, Inc. | Combination of blys inhibition and mycophenolate mofetil for treatment of autoimmune disease |
TWI489993B (en) | 2007-10-12 | 2015-07-01 | Novartis Ag | Compositions and methods of use for antibodies against sclerostin |
JP2011500715A (en) | 2007-10-16 | 2011-01-06 | ザイモジェネティクス, インコーポレイテッド | Combination of BLyS inhibitor and anti-CD20 agent for the treatment of autoimmune disease |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
CN103421113B (en) * | 2012-05-22 | 2018-01-19 | 武汉华鑫康源生物医药有限公司 | Anti- BLyS antibody |
CN104045713B (en) * | 2013-03-13 | 2019-02-12 | 江苏诺迈博生物医药科技有限公司 | The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody |
CN107586339B (en) * | 2016-07-06 | 2023-01-20 | 尚华科创投资管理(江苏)有限公司 | BLyS antibody and preparation method and application thereof |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | Treatment of diuretic resistance |
CN111787950A (en) | 2018-01-05 | 2020-10-16 | 科威迪亚治疗公司 | Methods for treating IL-6 mediated inflammation without immunosuppression |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087977A2 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
US20030012783A1 (en) * | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2396793A1 (en) * | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
PT2281843T (en) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
-
2002
- 2002-11-14 CA CA002467521A patent/CA2467521A1/en not_active Abandoned
- 2002-11-14 EP EP02802570A patent/EP1456347A4/en not_active Withdrawn
- 2002-11-14 AU AU2002364954A patent/AU2002364954A1/en not_active Abandoned
- 2002-11-14 WO PCT/US2002/036496 patent/WO2003055979A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087977A2 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
US20030012783A1 (en) * | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
Non-Patent Citations (1)
Title |
---|
See also references of EP1456347A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002364954A8 (en) | 2003-07-15 |
AU2002364954A1 (en) | 2003-07-15 |
CA2467521A1 (en) | 2003-07-10 |
EP1456347A2 (en) | 2004-09-15 |
WO2003055979A2 (en) | 2003-07-10 |
EP1456347A4 (en) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003055979A3 (en) | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS | |
MXPA02012434A (en) | Antibodies that immunospecifically bind to blys. | |
WO2002016411A3 (en) | Binding polypeptides and methods based thereon | |
WO2003054216A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
ATE470676T1 (en) | ANTI-VEGF-2 ANTIBODIES | |
WO2002097033A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2002094192A3 (en) | Antibodies against tumor necrosis factor delta (april) | |
BRPI0410129A (en) | therapeutic use of anti-cs1 antibodies | |
WO2002083849A3 (en) | Vascular endothelial growth factor 2 | |
WO2003057006A3 (en) | Use of antibodies against the muc18 antigen | |
BR0309095A (en) | Use of osteoprotegerin for the treatment and / or prevention of fibrotic disease. | |
BR0209812A (en) | Use of osteopontin for the treatment and / or prevention of neurological diseases. | |
BR0316723A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
WO2004013287A3 (en) | Antibodies against c3a receptor | |
WO2003085093A3 (en) | Antibodies that specifically bind to gmad | |
WO2004069183A3 (en) | Immune regulation based on the targeting of early activation molecules | |
BRPI0413404A (en) | pharmaceutical compositions, methods of treating or preventing cardiac dysfunction, methods of enhancing cardiac function, and identifying mif inhibitor | |
WO2004003144A3 (en) | Antibodies that specifically bind to reg iv | |
WO2005016236A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2002079377A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2004016753A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003042367A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003086301A3 (en) | Antibodies that specifically bind to tr2 | |
WO2002070563A3 (en) | Nuclear hormone receptor ligand binding domain | |
WO2002101394A3 (en) | Screening method which uses bnpi and dnpi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2467521 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002802570 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002802570 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |